SVR, n = 32 | Non-SVR, n = 7 | P values (SVR versus non-SVR groups) | |
---|---|---|---|
Gender, male/female | 24/8 | 5/2 | 0.77 |
Age, years | 57.8 ± 9.3 | 59.8 ± 5.6 | 0.58 |
Previous treatment: naïve/relapse/null | 14/17/1 | 3/2/2 | 0.13 |
AST, IU/L | 55.9 ± 50.1 | 44.7 ± 16.0 | 0.56 |
ALT, IU/L | 71.9 ± 70.6 | 51.1 ± 19.9 | 0.44 |
γ-GTP, IU/L | 62.1 ± 64.7 | 46.2 ± 27.9 | 0.53 |
Hemoglobin, g/dL | 14.6 ± 1.3 | 14.4 ± 1.6 | 0.72 |
Platelets, ×104/mm3 | 16.4 ± 5.2 | 14.3 ± 4.6 | 0.33 |
HCV RNA (logIU/mL) | 6.45 ± 0.68 | 6.81 ± 0.75 | 0.220 |
Treatment response | |||
RVR, n | 27 | 0 | <0.0001 |
EVR, n | 32 | 2 | <0.0001 |
IFNL4, major/minor/ND | 22/8/2 | 2/5/0 | 0.0727 |
Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.